| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Chengdu Easton Biopharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥59.35 |
| 52 Week High | CN¥64.25 |
| 52 Week Low | CN¥43.41 |
| Beta | 0 |
| 1 Month Change | 6.94% |
| 3 Month Change | 8.09% |
| 1 Year Change | 4.66% |
| 3 Year Change | 33.76% |
| 5 Year Change | n/a |
| Change since IPO | -20.57% |
Recent News & Updates
Shareholder Returns
| 688513 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.6% | 3.0% | 1.6% |
| 1Y | 4.7% | -12.9% | -15.1% |
Return vs Industry: 688513 exceeded the CN Pharmaceuticals industry which returned -12.9% over the past year.
Return vs Market: 688513 exceeded the CN Market which returned -15.1% over the past year.
Price Volatility
| 688513 volatility | |
|---|---|
| 688513 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 688513 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688513's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,392 | Mingxu Yuan | www.eastonpharma.cn |
Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry, and urinary system therapeutic categories.
Chengdu Easton Biopharmaceuticals Co., Ltd. Fundamentals Summary
| 688513 fundamental statistics | |
|---|---|
| Market cap | CN¥7.20b |
| Earnings (TTM) | CN¥240.60m |
| Revenue (TTM) | CN¥1.15b |
29.6x
P/E Ratio6.2x
P/S RatioIs 688513 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688513 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.15b |
| Cost of Revenue | CN¥236.50m |
| Gross Profit | CN¥917.76m |
| Other Expenses | CN¥677.16m |
| Earnings | CN¥240.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.00 |
| Gross Margin | 79.51% |
| Net Profit Margin | 20.84% |
| Debt/Equity Ratio | 7.8% |
How did 688513 perform over the long term?
See historical performance and comparison